ACCESS ASIA

Effective partnering and ASIA market assessment platform – ACCESS ASIA is a two-way gateway for cross-border biopharma deal-making. We connect innovative assets from China, South Korea, Japan, and across Asia with global partners, and give international companies a direct path to showcase their assets and enter Asian markets.

Who should present?

Global pharma/biotech companies:

  • Looking for out-licensing opportunities in Asia
  • With clinical-stage assets
  • Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas
  • Looking for equity investment opportunities in China (Chinese companies only)

Who are the attendees?

  • 40% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
  • 35% are Pharma/biotechs outside China looking for in-licensing opportunities to enrich pipeline in China and other regions
  • 20% are VCs and PEs looking for pharma/biotech investment opportunities in China

Why China ?

In/out-licensing is becoming the major business strategy among Chinese pharma.

China’s biotech deal market accelerated sharply in 2026H1. Out-licensing remained highly active, with 99 deals generating $4.97B in upfronts—nearly double the volume and value of 2025H1. In-licensing also rebounded strongly, with 14 deals and $55M in upfronts, up 40% and 175%, respectively, from 10 deals and $20M in 2025H1. Domestic partnering also surged, with transactions up 175% to 66 and upfronts rising 40% to $239M, highlighting broad-based momentum across China’s partnering market.

Why ACCESS ASIA?

Broad Chinese Strategic Partners Coverage

Compared to other conferences such as Bio Convention or Bio Showcase, ACCESS ASIA has the broadest coverage of Asia strategic partners and investors who are looking for in/out licensing opportunities.

A Two-Way Gateway

ACCESS ASIA connects innovative assets from China, South Korea, Japan, and across Asia with international partners, while giving global companies a direct path to showcase assets and enter Asian markets.

More Exposure via Different Channels

ACCESS ASIA promotes presenting companies through various channels in deluding asset listing on platform, video roadshow on live day and on demand, asset report distribution to our members, and promoting to targeted investors through email and social media.

Upcoming Events


Past Events

ACCESS ASIA is a series of events including ACCESS ASIA Spring BD Salon in Shanghai, East Meets West Mixing Dinner @ JPM, ACCESS ASIA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS ASIA Online Partnering.

20000+

Pharma/Biotech

network

26500+

Views

4800+

Requests



Cross-Border Licensing Trends